Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: ValuEngine, Inc.
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biocryst Pharmaceuticals Inc Prices Public Offering Of Common Stock

Wednesday, 31 Jul 2013 10:50pm EDT 

Biocryst Pharmaceuticals Inc announced the pricing of an underwritten public offering of 4,000,000 shares of common stock, offered at a price to the public of $4.40 per share. The gross proceeds from this offering to BioCryst are expected to be $17.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioCryst. BioCryst has granted the underwriters a 30-day option to purchase up to an aggregate of 600,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about August 6, 2013. BioCryst expects to use net proceeds of this offering for general corporate purposes, including funding clinical development of BCX4161, continued development of second generation hereditary angioedema compounds and pre-commercialization activities related to intravenous peramivir. Wells Fargo Securities, LLC and JMP Securities LLC are acting as joint book-running managers, with Noble Financial Capital Markets acting as co-manager for the offering. 

Company Quote

0.04 +0.35%
27 May 2015